🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

7,888 results for “1” Clear

  1. SODIUM CHLORIDE, VRDN-001 (Insulin-like growth factor-1 receptor [IGF-1R] inhibitor)

    Viridian Pharma Ltd

    Thyroid eye disease

    phase 3 small molecule active

    1 trial

  2. SODIUM CHLORIDE, VRDN-001 (Insulin-like growth factor-1 receptor [IGF-1R] inhibitor), VRDN-001 (Insulin-like growth factor-1 receptor [IGF-1R] inhibitor)

    Viridian Pharma Ltd

    Thyroid eye disease (TED)

    phase 3 small molecule active

    1 trial

  3. SOTORASIB, Dexamethasone 2mg Tablets, DOCETAXEL

    Amgen

    Previously treated locally advanced and unresectable or metastatic non-small cell lung cancer (NSCLC) with KRAS p.G12C mutation

    phase 3 small molecule active

    1 trial

  4. SOTORASIB, Stivarga 40 mg film-coated tablets, Lonsurf 20 mg/8.19 mg film-coated tablets, Vectibix 20 mg/ml concentrate for solution for infusion, Stivarga 40 mg film-coated tablets, Vectibix 20 mg/ml concentrate for solution for infusion, Lonsurf 15 mg/6.14 mg film-coated tablets

    Amgen

    Colorectal Cancer (CRC)

    phase 3 small molecule active

    1 trial

  5. SP-102

    Semnur Pharmaceuticals

    Lumbosacral Radicular Pain

    phase 3 small molecule active

    3 trials

  6. SPD476 (1.2g)

    Takeda

    Diverticulitis

    phase 3 small molecule completed

    1 trial

  7. SPD476, MMX™ mesalazine, 1.2g extended release tablet

    Takeda

    Diverticulitis

    phase 3 small molecule completed

    1 trial

  8. SPD489 low dose range (40mg, 80mg, and 100mg)

    Takeda

    Schizophrenia

    phase 3 small molecule terminated

    1 trial

  9. SPD503 (1 mg)

    Takeda

    Attention Deficit Disorder With Hyperactivity

    phase 3 small molecule completed

    1 trial

  10. SPECT : 123 I-FP-CIT (DATSCAN) and 123I-ADAM

    Ars Pharmaceuticals Irl Limited

    Amyotrophic Lateral Sclerosis

    phase 3 small molecule completed

    1 trial

  11. SPN-810

    SUPERNUS PHARMACEUTICALS, INC.

    Attention Deficit Hyperactivity Disorder

    phase 3 small molecule terminated

    1 trial

  12. SPN-810

    SUPERNUS PHARMACEUTICALS, INC.

    Attention Deficit Hyperactivity Disorder (ADHD)

    phase 3 small molecule terminated

    2 trials

  13. SPN-810 (18 mg)

    SUPERNUS PHARMACEUTICALS, INC.

    Attention Deficit Hyperactivity Disorder (ADHD)

    phase 3 small molecule completed

    2 trials

  14. STAGE-12

    BRIGHT MINDS BIOSCIENCES INC.

    Drug Abuse

    phase 3 other completed

    1 trial

  15. STAMARIL® , poeder en oplosmiddel voor suspensie voor injectie in voorgevulde spuit. Gelekoortsvaccin (levend)., STAMARIL® , poeder en oplosmiddel voor suspensie voor injectie in voorgevulde spuit. Gelekoortsvaccin (levend)., STAMARIL® , poeder en oplosmiddel voor suspensie voor injectie in voorgevulde spuit. Gelekoortsvaccin (levend).

    The George Institute

    Yellow fever

    phase 3 small molecule active

    1 trial

  16. STELARA 90 mg solution for injection in pre-filled syringe, Guselkumab, STELARA 45 mg solution for injection, Guselkumab - solution for injection in pre-filled syringe - 100 mg/mL

    Janssen-Cilag International N.V.

    Juvenile psoriatic arthritis

    phase 3 small molecule active

    1 trial

  17. STELARA 90 mg solution for injection in pre-filled syringe, Solution for injection in pre-filled syringe without Ustekinumab 45, Solution for injection in pre-filled syringe without Ustekinumab 90, STELARA 45 mg solution for injection, JNJ-77242113-AAC Placebo tablet, JNJ-77242113

    Janssen-Cilag International N.V.

    Active Psoriatic Arthritis

    phase 3 small molecule active

    1 trial

  18. STK-001, STK-001

    Stoke Therapeutics

    Dravet syndrome

    phase 3 small molecule active

    1 trial

  19. SV-BR-1-GM

    BriaCell Therapeutics

    Breast Cancer

    phase 3 mab active

    2 trials

  20. Safinamide 100 mg PLACEBO: Safinamide 100 mg PLACEBO film-coated tablets have the same composition as the relevant Investigational Medicinal Products except for the presence of Active Substance that is missing in the placebo formulations. The missing amount of active substance Safinamide methanesulfonate is replaced in the PLACEBO formulation with the same amount of Microcrystalline cellulose, one of the excipients already present in the authorised formulation, Xadago 100 mg film-coated tablets, Xadago 50 m

    Verona Pharma Ireland Limited

    PARKINSON’S DISEASE WITH MOTOR FLUCTUATIONS

    phase 3 small molecule active

    1 trial

  21. Salbutamol Aldo-Unión 100 microgramos/dosis suspensión para inhalación en envase a presión, Inhalation powder with lactose monohydrate and magnesium stearate, BREO ELLIPTA, Fluticasone furoate and Vilanterol inhalation powder 100 mcg/25 mcg

    Sandoz Pty Ltd

    Asthma

    phase 3 small molecule active

    1 trial

  22. Salbutamol HFA-134a

    GlaxoSmithKline

    Asthma

    phase 3 small molecule completed

    1 trial

  23. Saline Solution Basi 9 mg/ml solution for infusion, Felzartamab

    Biogen

    Kidney Transplant Recipients with Late Antibody-Mediated Rejection

    phase 3 small molecule active

    1 trial

  24. Saline, 0.9% Sodium Chloride Solution for Injection, JNJ-80202135, JNJ-80202135

    Janssen-Cilag International N.V.

    Hemolytic Disease of the Fetus and Newborn (HDFN)

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources